Budget 2027 MedTech: Why patient access is now a competitiveness issue
Ireland must move from being a world-class maker of MedTech to a world-class adopter of It
Budget 2027 was an opportunity for Ireland to maintain and strengthen its position as a leading global MedTech hub. Increasingly, global companies are assessing countries not just on where products can be made, but on how effectively healthcare systems adopt innovation. Ireland needs to demonstrate that it goes beyond just the development and manufacture of healthcare technologies.
Ireland currently ranks among the top 5 MedTech hubs in the world, which includes more than 550 companies employing approximately 50,000 people and generating around 20 Billion in exports every year. But when global companies are deciding where to invest, they no longer look to where products can be developed and made, they look at how quickly a countries health system evaluates, adopts and pays for new technology.
This is the lens through which the sector should evaluate the strength of the 2027 Budget. There were welcome measures for innovation and competitiveness, plus a renewed focus on the forthcoming National Life Sciences Strategy. But it also highlighted the wider challenge: simply aiming to attract investment is not enough, Ireland must support innovation across the full MedTech ecosystem, from R&D to evaluation, adoption and patient access.
The most significant announcement wasn’t about tax
In his Budget statement, the Minister outlined a more strategic approach to medicines and health technologies, linked to the forthcoming National Life Sciences Strategy. The aim being to create a more predictable, sustainable and forward-looking framework for planning, investment and access. For MedTech companies, this is key.
Countries that are seen as early adopters of healthcare innovation are usually more attractive destinations for clinical studies, commercial investment, product launches and strategic partnerships. This also naturally creates stronger feedback loops between industry, healthcare providers and researchers, which supports future innovation.
The Government's recognition of this reality is welcome. The challenge now is ensuring that the National Life Sciences Strategy delivers on things that make a real difference. This could include:
A dedicated Office of Life Sciences with central responsibility for coordinating life sciences policy across Government, the HSE, State Agencies, industry and academia
Structured plans for accelerating early technology adoption and pilot programmes in hospitals to enable real life clinical trials
A clear route focused on assessing and reimbursing medical devices and diagnostics, different to the pathway for medicines
HSE procurement rewarding value and innovation not just lowest upfront costs
Defined timelines, so companies can plan Irish launches with more confidence.
Innovation advancements
Budget 2027 also introduced enhancements to Ireland’s R&D corporation tax credit.
The credit remains at 35%
The limit for R&D subcontracted to third parties will increase from €100,000 to €200,000
The limit for outsourcing to universities and other third-level institutions will increase from 15% to 20% of qualifying expenditure
The first-instalment payment threshold will increase from €87,500 to €105,000
For regulated clinical trials, the fact that a trial is regulated will be capable of satisfying the scheme’s science test.
For a sector built on continual innovation, these are positive developments.
These changes matter because medical technology innovation increasingly relies on companies, universities, hospitals, research centres and specialist partners collaborating closely. The more flexible subcontracting rules should support that model, while the clinical-trials measures should help reduce uncertainty for companies involved in regulated research.
The direction of travel is positive, but it is targeted rather than transformative. What the Budget does not appear to deliver on is on the broader expansion of qualifying R&D activity sought by parts of the life sciences sector, including wider support for process innovation and connected-party research.
For MedTech businesses specifically, the practical test will be whether these measures mean Ireland is seen to be a more competitive location for the next generation of innovation-intensive projects.
Competitiveness is key
The reality is that Ireland's future success in MedTech will not be determined by one single Budget. The sector's long-term competitiveness depends on a range of interrelated factors:
Access to skilled talent
Housing affordability and availability
Energy infrastructure and grid capacity
Planning and infrastructure delivery
Research and innovation capability
Healthcare innovation and patient access
Budget 2027 included personal tax changes intended to support take-home pay, together with infrastructure and energy commitments, and although those measures are important, their value to MedTech will depend on delivery, particularly around housing, grid capacity, planning and transport.
The question for Ireland is not whether it has been successful in attracting MedTech investment, it is whether it can remain successful over the next decade. Talent availability, quality of life, infrastructure and innovation ecosystems will determine the answer.
From manufacturing leader to healthcare innovation leader
Ireland has already demonstrated its capability as a global MedTech manufacturing hub. So, the next opportunity could well be to become a recognised leader in healthcare innovation adoption. The Government's commitment to a more strategic approach to medicines and health technologies definitely goes a long way to creating an opportunity to strengthen the connection between healthcare delivery, innovation and industrial policy.
If Ireland can improve patient access to innovative technologies while maintaining a strong environment for research, manufacturing and commercialisation, it will create a compelling value proposition for global investors.
However, this is not simply about supporting industry, it is about ensuring that Irish patients benefit sooner from the innovations being developed, tested and manufactured here.
Looking ahead
For MedTech, Budget 2027 is best described as positive but measured. The R&D changes are useful, the focus on access to medicines and health technologies is welcome, and competitiveness remains a stated national priority. Yet none of these measures alone answer the central question: how will Ireland convert its manufacturing strength into a deeper capability to develop, evaluate and adopt healthcare innovation?
Because in an increasingly competitive world, the countries that attract the next generation of MedTech investment will not simply be those that make innovation, it will be those that embrace it.
What MedTech companies should do now
The higher limits may allow more of your R&D spend with external partners and third-level institutions to qualify
The higher first-instalment threshold means more of the credit can be received in the first year, which can be significant for earlier-stage and scaling businesses
Regulated trials that previously sat outside claims, or needed extensive technical support to justify, may now be easier to bring within the scheme
The detail of the access and adoption reforms is still to be shaped. Companies that bring practical evidence of today's barriers will have the most influence.
Related content
